By Marie Rosenthal
Although the feds have taken a closer look at the 340B Drug Pricing Program that allows qualifying hospitals to purchase drugs at a reduced rate, the focus seems to be on how hospitals are using the discounts, rather than the role of manufacturers in the program, experts said.
A lawsuit brought by four national hospital organizations representing hospitals and other stakeholders in the 340B Drug Pricing Program might direct that attention back to the manufacturers.